Cue Biopharma, Inc.
CUE
$0.7007
$0.04526.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.83% | 69.16% | 149.53% | 363.98% | 1,525.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.83% | 69.16% | 149.53% | 363.98% | 1,525.00% |
| Cost of Revenue | -16.43% | -12.72% | 10.07% | 15.78% | 22.56% |
| Gross Profit | 22.43% | 24.87% | 5.95% | 2.59% | -3.57% |
| SG&A Expenses | -13.32% | -7.97% | -27.98% | -20.01% | -13.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.58% | -11.49% | -3.25% | 3.37% | 9.84% |
| Operating Income | 19.61% | 20.00% | 14.22% | 8.84% | 2.59% |
| Income Before Tax | 18.78% | 19.83% | 14.03% | 9.42% | 3.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.78% | 19.83% | 14.03% | 9.42% | 3.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.78% | 19.83% | 14.03% | 9.42% | 3.65% |
| EBIT | 19.61% | 20.00% | 14.22% | 8.84% | 2.59% |
| EBITDA | 19.64% | 19.91% | 13.95% | 8.43% | 2.02% |
| EPS Basic | 37.64% | 32.50% | 24.36% | 23.28% | 21.00% |
| Normalized Basic EPS | 37.27% | 32.13% | 24.52% | 23.56% | 21.70% |
| EPS Diluted | 37.64% | 32.50% | 24.36% | 23.28% | 21.00% |
| Normalized Diluted EPS | 37.27% | 32.13% | 24.52% | 23.56% | 21.70% |
| Average Basic Shares Outstanding | 33.05% | 23.01% | 13.19% | 17.79% | 21.51% |
| Average Diluted Shares Outstanding | 33.05% | 23.01% | 13.19% | 17.79% | 21.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |